Lake Street analyst Thomas Flaten lowered the firm’s price target on Optinose to $3 from $4 and keeps a Buy rating on the shares after the company reported full Q1 results following its previous pre-release. The firm believes shares can more appropriately reflect the opportunity for XHANCE with the recent equity raise removing some financing overhang, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPTN:
- Optinose sees 2024 XHANCE net revenue $85M-$95M
- Optinose reports Q1 EPS (12c), consensus (11c)
- Optinose Reports First Quarter 2024 Financial Results and Recent Operational Highlights
- OPTN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Optinose Announces Reporting Date for First Quarter 2024 Financial Results